Education
About Us
Working with TipRanks
Follow Us
AnaptysBio (GB:0HFQ)
:0HFQ
0HFQ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.87 - $41.25
Previous CloseN/A
Volume238.00
Average Volume (3M)3.72K
Market Cap
$513.06M
Enterprise Value$904.86M
Total Cash (Recent Filing)$123.08M
Total Debt (Recent Filing)$16.04M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
May 08, 2025EPS Estimate
-1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.20
Shares Outstanding30,666,780
10 Day Avg. Volume306
30 Day Avg. Volume3,722
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.49
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.91
Enterprise Value/Ebitda-9.76
Forecast
1Y Price Target
$41.78Price Target Upside156.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceANAB reported $43.1M in revenue, well above estimates, driven by commercial milestones from GSK’s Jemperli sales.
ValuationShares trading with an EV of ~$50MM are seen as undervalued, as NPV analysis of rosnilimab in RA alone suggests $35/share.
Bears Say
Clinical TrialsANAB announced that the Ph. IIb trial of ANB032 did not meet the primary EASI-75 endpoint nor any secondary endpoints and will discontinue further development.
---
0HFQ FAQ
What was AnaptysBio’s price range in the past 12 months?
AnaptysBio lowest share price was $11.87 and its highest was $41.25 in the past 12 months.
What is AnaptysBio’s market cap?
AnaptysBio’s market cap is $513.06M.
When is AnaptysBio’s upcoming earnings report date?
AnaptysBio’s upcoming earnings report date is May 08, 2025 which is in 57 days.
How were AnaptysBio’s earnings last quarter?
AnaptysBio released its earnings results on Feb 27, 2025. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$1.619 by $0.899.
Is AnaptysBio overvalued?
According to Wall Street analysts AnaptysBio’s price is currently Undervalued.
Does AnaptysBio pay dividends?
AnaptysBio does not currently pay dividends.
What is AnaptysBio’s EPS estimate?
AnaptysBio’s EPS estimate is -1.3.
How many shares outstanding does AnaptysBio have?
AnaptysBio has 30,666,780 shares outstanding.
What happened to AnaptysBio’s price movement after its last earnings report?
AnaptysBio reported an EPS of -$0.72 in its last earnings report, beating expectations of -$1.619. Following the earnings report the stock price went down -0.055%.
Which hedge fund is a major shareholder of AnaptysBio?
Currently, no hedge funds are holding shares in GB:0HFQ
---
AnaptysBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.78 (156.00% Upside)
$41.78 (156.00% Upside)
Blogger Sentiment
Bullish
GB:0HFQ Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.54%
12-Months-Change
Fundamentals
Return on Equity
-182.71%
Trailing 12-Months
Asset Growth
6.95%
Trailing 12-Months
Company Description
AnaptysBio
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
---
0HFQ Stock 12 Month Forecast
Average Price Target
$41.78
▲(156.00% Upside)
Technical Analysis
Best Analysts Covering 0HFQ
1 Year
1 Year Success Rate
9/17 ratings generated profit
1 Year Average Return
-23.24%
reiterated a buy rating 9 days ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of -23.24% per trade.
---